Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drugs
- Pharmaceuticals
- Therapeutic
- Disease
- Delivery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6891
The Licensor receives royalty revenues on Orapred products, a product acquired in 2004 and subLicensed in 2006.
IPSCIO Record ID: 5768
The Orapred product line is also used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer. Orapred ODT utilizes a proprietary orally disintegrating tablet technology to provide a taste-masked, non-refrigerated and convenient formulation of prednisolone. Licensor retains rights outside North America.
New Drug Applications
Abbreviated New Drug Applications
Orapred (Prednisolone Sodium Phosphate Oral Solution), 20.2 mg/ 5 ML, (equivalent to 15 mg (base)/ 5 ML) – ANDA 75-117
Orapred RT (Prednisolone Sodium Phosphate Oral Solution), 20.2 mg/ 5 ML, (equivalent to 15 mg (base)/ 5 ML) – ANDA 77-485
505(B)(2) New Drug Application
Orapred ODT (Prednisolone Sodium Phosphate
Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg Prednisolone base) – NDA 21-959
Development Licensed Patents
Patent/Application Number
OraSolv® Technology
US 5178878 A
US 08/468,913
CA 2,061,917
PakSolv® Technology
US 6,155,423
CA 2284132
US 6,269,615
US 6,311,462
DuraSolv® Technology
US 6,024,981
US 6,221,392
CA 2284663
Licensed Trademarks
Orapred
Orapred ODT
CIMA
CIMA LABS INC.
OraSolv®
PakSolv®
DuraSolv®
CIMA, CIMA LABS INC. OraSolv®, PakSolv®, DuraSolv®, and are Cima Trademarks.
Taste Masking Related Licensed Patents
Patent/Application Number
Pleasant Tasting Aqueous Liquid Composition of a Bitter-Tasting Drug
Anaebonam, Aloysius O.
Clemente, Emmett
Fawzy, Abdel A.
08/692,081
5763449
United States
09/011,156
5962461
United States
2260852
2260852
Canada
991273
Mexico
Room Temperature Stable Aqueous Liquid Pharmaceutical Composition
Emmett Clemente, Bhiku Patel, Kuljit Bhatia, Frank L. Sorgi, and Emil D. Kakkis
Medicis Pharmaceutical Corporation, Ascent Pediatrics Inc., BioMarin Pharmaceutical Inc.
11/066,113
United States
PCT/US2005/006576
Transferred Inventory of Orapred
Description
8 oz. Trade bottles
Lot Numbers
Expiration Date
Units
NDC Number
RM0421
39416
24204
68135-455-02
RM0501
39447
12108
Institutional packs
RM0502
39447
12192
RM0504
39478
10740
8 oz. Samples
RM0502A
39447
12960
68135-455-03
6 pack, 20 ml samples
RM0505
39538
10656
68135-455-04
8 oz. Authorized generic bottles
RM0504A
39538
13315
68135-455-01
RM0505A
22408
05PSP05
39568
24144
NA
05PSP06
39568
24288
05PSP07
39599
24348
IPSCIO Record ID: 28457
Mastocytosis is a group of rare disorders of both children and adults caused by the presence of too many mast cells (mastocytes) and CD34+ mast cell precursors in a person's body. You can find mast cells in skin, lymph nodes, internal organs (such as the liver and spleen) and the linings of the lung, stomach, and intestine. Mast cells play an important role in helping your immune system defend these tissues from disease. Mast cells attract other key players of the immune defense system to areas of your body where they are needed by releasing chemical alarms such as histamine and cytokines.
IPSCIO Record ID: 7576
An orally disintegrating tablet or orodispersible tablet (ODT) is a drug dosage form available for a limited range of over-the-counter and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole.
'Licensed Patents' shall mean Intellectual Property solely relating to the Product and US Patent Application 2007/01.90144 (Novel formulation for sublingual drug delivery and use thereof) and all corresponding know-how, patents, patent applications, continuation applications, continuation, etc.
The first product the Licensee will develop with this technology is sublingual sildenafil. This therapy is used for erectile disfuction.
The Licensee is to complete the required studies and regulatory tasks to commercialize products using the oral dissolving technology and is responsible for any all clinical trials related to the development of products using ODT technology.
